Leptomeningeal Carcinomatosis Clinical Trial
Official title:
A Phase I Safety and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent, Progressive or Refractory Neoplastic Meningitis
This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent neoplastic meningitis.
Neoplastic meningitis refers to the deposition of malignant cells in the lining (leptomeninges) of the brain and spine. Neoplastic meningitis from solid tumors most often occurs in patients with advanced systemic disease who have failed prior chemotherapy; it is also frequent in patients with CNS parenchymal metastasis. Patient survival remains low, and better treatments are needed to penetrate the blood brain barrier and treat the entire neuraxis. RTA 744 is a close chemical analogue of the well characterized anti-cancer agent doxorubicin. Unlike doxorubicin, RTA 744 has shown ability to cross the blood brain barrier and to achieve high concentration in CNS tumor tissue in animal models. Dose escalation will continue as pre-determined until first occurrence of a dose-limiting toxicity. Maximum tolerated dose will be determined as defined in protocol. Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00830245 -
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT02939300 -
Ipilimumab and Nivolumab in Leptomeningeal Metastases
|
Phase 2 | |
| Not yet recruiting |
NCT03613181 -
ANG1005 in Leptomeningeal Disease From Breast Cancer
|
Phase 3 | |
| No longer available |
NCT02755987 -
Expanded Access to ANG1005 for Individual Patients
|
N/A |